<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>23(4)</volume><submitter>Xu J</submitter><funding>no funding</funding><pubmed_abstract>Angiotensin-converting enzyme 2 (ACE2) is identified as the functional receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the ongoing global coronavirus disease-2019 (COVID-19) pandemic. This study aimed to elucidate potential therapeutic avenues by scrutinizing approved drugs through the identification of the genetic signature associated with SARS-CoV-2 infection in individuals with asthma. This exploration was conducted through an integrated analysis, encompassing interaction networks between the ACE2 receptor and common host (co-host) factors implicated in COVID-19/asthma comorbidity. The comprehensive analysis involved the identification of common differentially expressed genes (cDEGs) and hub-cDEGs, functional annotations, interaction net</pubmed_abstract><journal>Cell cycle (Georgetown, Tex.)</journal><pagination>405-434</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11529202</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks.</pubmed_title><pmcid>PMC11529202</pmcid><pubmed_authors>Abbas AH</pubmed_authors><pubmed_authors>Abdulsalam Khaleel R</pubmed_authors><pubmed_authors>Bahrami A</pubmed_authors><pubmed_authors>Fahmi Fawy K</pubmed_authors><pubmed_authors>Arias Gonzales JL</pubmed_authors><pubmed_authors>Zaidan HK</pubmed_authors><pubmed_authors>Faisal Mutee A</pubmed_authors><pubmed_authors>Xu J</pubmed_authors><pubmed_authors>Gehlot A</pubmed_authors><pubmed_authors>Ruiz-Balvin MC</pubmed_authors><pubmed_authors>Amin AH</pubmed_authors><pubmed_authors>Akhavan-Sigari R</pubmed_authors><pubmed_authors>Imannezhad S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks.</name><description>Angiotensin-converting enzyme 2 (ACE2) is identified as the functional receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the ongoing global coronavirus disease-2019 (COVID-19) pandemic. This study aimed to elucidate potential therapeutic avenues by scrutinizing approved drugs through the identification of the genetic signature associated with SARS-CoV-2 infection in individuals with asthma. This exploration was conducted through an integrated analysis, encompassing interaction networks between the ACE2 receptor and common host (co-host) factors implicated in COVID-19/asthma comorbidity. The comprehensive analysis involved the identification of common differentially expressed genes (cDEGs) and hub-cDEGs, functional annotations, interaction net</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2026-06-02T06:41:43.705Z</modification><creation>2026-05-25T03:07:50.816Z</creation></dates><accession>S-EPMC11529202</accession><cross_references><pubmed>38640424</pubmed><doi>10.1080/15384101.2024.2340859</doi></cross_references></HashMap>